New heart attack data boost AZ’s Brilinta
A new sub-analysis of data from a phase 3 trial shows AstraZeneca’s Brilinta cuts the risk of cardiovascular death by 29% in high risk patients.
X
New heart attack data boost AZ’s Brilinta
https://pharmaphorum.com/news/new-heart-attack-data-boost-azs-brilinta/
